Drug Trial Radar · NCT01347190
Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis
Last checked: Nov 19, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Apr 2011
Primary completion
Aug 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to assess safety and tolerability of a single dose of study-drug administered to Cystic Fibrosis (CF) patients.
Conditions
- Cystic Fibrosis
Interventions
CR002 Liquid APIBiological
A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
PlaceboBiological
A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse eventsTime frame: 44 Days (Day -21 to Day 22)
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Site 11
Sofia, Bulgaria
Site 12
Varna, Bulgaria
Site 30
Debrecen, Hungary
Site 24
Bialystok, Poland
Site 22
Gdansk, Poland
Site 21
Poznan, Poland
Site 20
Rabka-Zdrój, Poland
Site 23
Warsaw, Poland
Site 42
Papworth Hospital, United Kingdom
Site 40
Penarth, United Kingdom
Site 41
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.